Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / Jun / A Ray of Hope Against Aggressive Cancers
Oncology Oncology Screening and monitoring

A Ray of Hope Against Aggressive Cancers

A new method of analyzing FFPE tissues for telomerase activity could be used in aggressive cancer diagnostics

By George Francis Lee 06/27/2022 News 2 min read

Share

One possible culprit for immortality in human cancer cells is the presence of human telomerase reverse transcriptase (hTERT) activity. The correlation between hTERT’s enzymatic activity and TERT expression levels in cancer has yet to be fully understood, but – building on previous work that established hTERT phosphorylation at threonine 249 (p-hTERT) in specific liver and pancreatic cancers – a Japanese research team has now identified that phosphorylated hTERT is common in many cancers with more aggressive characteristics.

The team developed a mouse monoclonal antibody capable of recognizing phosphorylated hTERT at threonine 249, reportedly the first effective tool for visualizing hTERT-RdRP in cancer through formalin-fixed, paraffin-embedded tissues. They then analyzed 1,523 cancer specimens with a variety of sites of origin to better understand the clinicopathological characteristics of hTERT-RdRP-active cancer.

The results showed that p-hTERT is associated with higher overall risk in aggressive lung, pancreatic, and liver cancers – regardless of TNM staging. Expression of p-hTERT is also strongly associated with “markers of squamous cell differentiation and aggressive features,” indicating that this process is common in aggressive cancers. The team discovered that p-hTERT is associated with a number of oncological features such as “adenosquamous carcinoma (lung and pancreas), invasive type of cancer (lung), high serum alpha-fetoprotein level (liver), and triple-negative status (breast)” (1). 

Though p-hTERT may have prognostic value in lung, pancreatic, and liver cancers, this was not evidenced in colon and stomach cancers. The team also discovered that, although p-hTERT expression increased alongside mitosis score in all of the aforementioned cancers, expression in colon and stomach cancers decreased as pathological grade increased. One potential reason for this difference is that other mechanisms, possibly in the tumor microenvironment, may regulate p-hTERT expression in these cancers.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Y Matsuda et al., J Pathol, 257, 172 (2022). PMID: 35094384.

About the Author(s)

George Francis Lee

Interested in how disease interacts with our world. Writing stories covering subjects like politics, society, and climate change.

More Articles by George Francis Lee

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.